BioVision is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. BioVision aims to provide innovative, high quality research tools to accelerate drug discovery in disease-related areas like cancer, diabetes, obesity, Alzheimer's disease, etc. We achieve these goals through a well-defined core strategy and a company culture that fosters integrity, openness, and collaboration, and rewards customer focus. BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.
4
Total Investments
4
Portfolio Companies
-
Exits
1
Industries
General Information
Industries
Biotechnology
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Biovision Ventures
Recent Investments (4)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series B | •••••• | Jan 2026 | |
| Series A | •••••• | Apr 2025 | |
| Seed Round | •••••• | May 2024 | |
| Series B | •••••• | Jun 2022 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.